Anti-Leukemic Activity of Brassica-Derived Bioactive Compounds in HL-60 Myeloid Leukemia Cells

María Ángeles Núñez-Sánchez 1, María Antonia Martínez-Sánchez 1,2, Marina Verdejo-Sánchez 2, Paula García-Ibáñez 3, Alba Oliva Bolarín 1, Bruno Ramos-Molina 1,*#3, Diego A. Moreno 4,*# and Antonio J. Ruiz-Alcaraz 2

Abstract: Acute myeloid leukemia (AML) is a cancer of the myeloid blood cells mainly treated with chemotherapy for cancer remission, but this non-selective treatment also induces numerous side effects. Investigations with bioactive compounds from plant-derived foods against cancer have increased in the last years because there is an urgent need to search for new anti-leukemic agents possessing higher efficacy and selectivity for AML cells and fewer negative side effects. In this study, we analyzed the anti-leukemic activity of several phytochemicals that are representative of the major classes of compounds present in cruciferous foods (glucosinolates, isothiocyanates, hydroxycinnamic acids, flavonols, and anthocyanins) in the human acute myeloid leukemia cell line HL-60. Our results revealed that among the different Brassica-derived compounds assayed, sulforaphane (SFN) (an aliphatic isothiocyanate) showed the most potent anti-leukemic activity with an IC50 value of 6 μM in dose-response MTT assays after 48 h of treatment. On the other hand, chlorogenic acid (a hydroxycinnamic acid) and cyanidin-3-glucoside (an anthocyanin) also displayed anti-leukemic potential, with IC50 values of 7 μM and 17 μM after 48 h of incubation, respectively. Importantly, these compounds did not show significant cell toxicity in macrophages-like differentiated cells at 10 and 25 μM, indicating that their cytotoxic effects were specific to AML cancer cells. Finally, we found that these three compounds were able to induce the NRF2/KEAP1 signaling pathway in a dose-dependent manner, highlighting SFN as the most potent NRF2 activator. Overall, the present evidence shed light on the potential for using foods and ingredients rich in anticancer bioactive phytochemicals from Brassica spp.

Keywords: Brassica; phytochemicals; leukemia; cancer; sulforaphane; phenolic compounds
of the presence of residual leukemic-resistant cells [6]. Thus, there is an urgent need for new anti-leukemic agents with better efficacy and selectivity for cancer cells and fewer negative side effects [7–9]. In this regard, dietary sources of phytochemicals and their bioactive metabolites are good candidates for searching for active agents in the treatment of leukemia [10–14].

In addition to essential nutrients, vegetables are rich sources of phytochemicals with potential health benefits. Specifically, among the most important vegetables are those belonging to the *Brassicaceae* family. This includes several crops, such as broccoli, cabbages, and radishes, with a high socioeconomic relevance [15]. They are known to be rich in phenolic compounds and other biomolecules such as glucosinolates (GSL). The latter are stable secondary metabolites that, by the action of the myrosinase enzyme (EC 3.2.1.147), are hydrolyzed producing a variety of bioactive compounds such as isothiocyanates (ITC) [16–18]. Remarkably, certain ITCs are able to induce Phase II detoxification enzymes and thus, exert anti-carcinogenic effects in a myriad of experimental models [19–22]. In addition, glycosylated and acylated derivatives of cinnamic acids, flavonols, and anthocyanins (mainly cyanidins) are the major and ubiquitous representative phytochemicals in cruciferous vegetables [23–25]. Emerging evidence has proposed that certain dietary bioactive compounds may have potential interest in cancer therapy. However, the antileukemic effects of bioactive compounds present in *Brassica* spp. remain poorly understood [26].

Accumulating evidence indicates that *Brassica* spp. phytochemicals may exert antitumoral activities by activating nuclear factor erythroid 2-related factor 2 (NRF2) which is a master modulator of redox homeostasis [27]. For example, sulforaphane (SFN), the bioactive ITC derived from the aliphatic glucoraphanin (GRA) and very abundant in cruciferous vegetables, has been shown to be a potent NRF2 activator with anti-carcinogenic properties in a number of experimental models [16,28,29]. On the other hand, the indole-3-carbinol (I3C), and phenolic acids (e.g., chlorogenic acid, CQA), or flavonoids (e.g., rutin), have been also tested in vitro and in vivo to explore their therapeutic potential in the treatment of leukemia, providing the basis for new alternative therapies [11,30–32]. However, the activity of *Brassica* spp. bioactive compounds other than SFN as NRF2 inducers in cancer cells remain largely unexplored.

In this work, we have analyzed the anti-leukemic activity of a set of phytochemicals representing the major classes of bioactive compounds in cruciferous foods (GSL, ITC, hydroxycinnamic acids, flavonols, and anthocyanins) as well as the activity of the most potent anticancer compounds as NRF2 inducers in human AML cells.

2. Results

2.1. Analysis of the Anti-Leukemic Potential of *Brassica* spp. Phytochemicals in HL-60 Cells

The chemical and structural properties of the natural bioactive compounds included in this study are shown in Figure 1. The screening of the potential anti-leukemic activity of the compounds was initially measured by MTT assay at relatively high doses (10 µM, 25 µM, and 50 µM) of all the compounds for three time-points: 24, 48, and 72 h.

Then, selected active compounds were subjected to further dose-response analysis by adding lower doses (0.5 µM, 1 µM, 5 µM) to the assays at 48 and 72 h (Figure 2). Among all the tested compounds SFN had the highest effect on cell viability, as it was able to decrease the viability of the active proliferative cells at the two higher doses tested (25 µM and 50 µM), reaching cytotoxicity levels above 95% for all time points (24, 48 and 72 h) (Figure 2A). In fact, SFN already reduced the viability of the cells to levels below 50% for all time points with a 10 µM dose (Figure 2A).
Figure 1. Bioactive compounds selected for this study as commonly present and characteristic of Brassica spp. foods and ingredients. Dash arrows connect precursors and bioactive metabolites.

Dose-response assays performed at 48 and 72 h showed that IC$_{50}$ values of SFN were 5.9 µM and 11.3 µM, respectively (Table 1). On the contrary, other aliphatic GSLs such as GRA, GRE, and GER did not show any significant effects on HL-60 viability, even at 50 µM [33].

Table 1. IC$_{50}$ values of active cytotoxic compounds.

| Compound       | IC$_{50}$ (µM) | Treatment Time |
|----------------|----------------|----------------|
|                | 48 h           | 72 h           |
| SFN            | 5.9 ± 0.3      | 11.3 ± 0.5     |
| CQA            | 17.4 ± 0.7     | 28.9 ± 0.7     |
| C3G            | 7.0 ± 1.0      | 21.9 ± 0.3     |

Results represent IC$_{50}$ values (µM) as mean ± SD following 48 and 72 h exposure of proliferative HL-60 cells to different doses (0.5 µM, 1 µM, 5 µM, 10 µM, 25 µM, and 50 µM) of active phytochemicals obtained from the MTT assay ($n = 3$). IC$_{50}$ values were not determined for those compounds that did not reduce cells viability below 50%. SFN, sulforaphane; CQA, Chlorogenic acid; C3G, cyanidin-3-glucoside chloride; I3C, indole-3-carbinol; DIM, 3,3′-Diindolylmethane.
Int. J. Mol. Sci. 2022, 23, x FOR PEER REVIEW 4 of 12

Figure 2. Anti-leukemic effect of Brassica spp. phytochemicals in HL-60 cells. The screening of the potential anti-leukemic activity of the Brassica spp. phytochemicals were initially done with high doses (10 µM, 25 µM, and 50 µM) of all compounds for 24, 48, and 72 h. Then, the selected more active compounds (SFN, CQA, and C3G) were subjected to further dose-response analysis by testing lower doses (0.5 µM, 1 µM and 5 µM) at 48 and 72 h. Data represents % of cell viability ± SD of HL-60 human leukemia cells in the presence of active Brassica-derived compounds measured by MTT assays (n = 3, three independent experiments performed in triplicate). (A) Anti-leukemic potential of SFN. (B) Anti-leukemic potential of CQA. (C) Anti-leukemic potential of C3G. (D) Anti-leukemic potential of I3C. (E) Anti-leukemic potential of DIM. SFN, sulforaphane; CQA, Chlorogenic acid; C3G, cyanidin-3-glucoside chloride; I3C, indole-3-carbinol; DIM, 3,3′-Diindolmethane.

CQA also showed a strong anti-AML effect, leading to a significant reduction of cell viability at all tested times (Figure 2B). This effect was especially remarkable after 48 and 72 h treatments, with the viability reduced to 13% and 11% respectively for the higher dose and even lower than 50% with the 25 µM treatment (Figure 2B), and IC$_{50}$ values of 17.4 and 28.9 µM (Table 1). By contrast, sinapic acid (SIA) did not have any effect whatsoever on cell viability in HL-60 cells [33].

The treatment of HL-60 cells with cyanidin-3-glucoside chloride (C3G), an anthocyanin, presented a mild but constant effect already at 24 h, showing cell viability levels around 40% when treated with 10–50 µM doses (Figure 2C). This effect was even more potent at longer times (48 h and 72 h) for the higher doses (25 and 50 µM), lowering cell viability...
below 20% (Figure 2C). IC\textsubscript{50} values of C3G were 7.0 \(\mu\text{M}\) for the 48-h treatment and 21.9 \(\mu\text{M}\) for 72 h (Table 1).

In the case of the indolic group of compounds, including glucobrassicin (GBS), I3C, and DIM, only I3C and DIM showed significant antiproliferative effects. While I3C was able to reduce the viability of the cells down to 38%, but just at the shorter time (24 h) with the maximum dose (Figure 2D), DIM showed a mild effect with the higher dose at all the three time-points assayed, reaching a maximum cytotoxicity of 75% at 48 h (25% viability), (Figure 2E). GBS did not show any effect on cell viability in any experimental condition.

2.2. Effects of Brassica spp. Phytochemicals in the Cell Viability of Macrophage-like Differentiated HL-60 Cells

The previously described viability results were further compared to those obtained with differentiated cells to verify the specificity of the anti-tumor/cytotoxic effect of the active compounds upon the proliferative leukemia cells [34,35]. The treatment of differentiated HL-60 cells with the active compounds did not show significant differences in cell viability with any of the doses at 48 h, with the only exception of SFN at concentrations higher than 10 \(\mu\text{M}\), for which it produced a significant cytotoxic effect (Table 2).

| Compound | 10 \(\mu\text{M}\) | 25 \(\mu\text{M}\) | 50 \(\mu\text{M}\) |
|----------|-----------------|-----------------|----------------|
| SFN      | 98.2 ± 12.1     | 87.6 ± 6.8      | 70.0 ± 17.5 *  |
| CQA      | 113.5 ± 19.2    | 114.4 ± 20.6    | 108.7 ± 11.8   |
| C3G      | 113.7 ± 24.4    | 108.1 ± 7.4     | 107.2 ± 12.8   |
| I3C      | 93.6 ± 8.0      | 99.5 ± 5.4      | 95.1 ± 10.4    |
| DIM      | 101.5 ± 22.7    | 117.7 ± 27.2    | 104.8 ± 13.5   |

Values are expressed as the mean ± SD following a 48-h exposure of HL-60 cells differentiated cells to the active cytotoxic compounds obtained from three different MTT assays (\(n = 3\)). * \(p < 0.05\). SFN, sulforaphane; CQA, Chlorogenic acid; C3G, cyanidin-3-glucoside chloride; I3C, indole-3-carbinol; DIM, 3,3\textsuperscript{′}-Diindolmethane.

Nonetheless, the administration of SFN at 10 \(\mu\text{M}\) to differentiated cells did not cause significant cytotoxicity. Overall, these results indicate that the cytotoxic effect of the compounds was remarkably higher in proliferative leukemia cells with respect to differentiated macrophage-like cells.

2.3. Potential of Brassica spp. Phytochemicals as NRF2 Inducers in Human Acute Myeloid Leukemia HL-60 Cells

In order to test the effect of the most potent anti-leukemic compounds (SFN, CQA, and C3G) on NRF2 activation in human acute myeloid leukemia HL-60 cells, we performed gene expression analysis by RT-qPCR of NFR2 (encoded by the NFE2L2 gene) and related genes. As shown in Figure 3A and Figure S1, SFN, CQA, and C3G were able to markedly induce the expression levels of the NRF2-target genes including HMOX, NQO1, and GSTA1 in a dose-dependent fashion.

Furthermore, none of these bioactive compounds was able to increase the gene expression of other antioxidant enzymes such as CAT, SOD1, or GPX1 (Figures S2 and S4), suggesting that these Brassica-derived phytochemicals are able to specifically induce the NRF2 pathway, but not other enzymes involved in redox homeostasis [33,36]. Remarkably, none of the tested compounds overactivated NRF2-dependent genes in HL-60 macrophage-like differentiated cells (Figure 3 and Figure S3), suggesting that NFE2L2 induction was specific to cancer cells.
Figure 3. Brassica spp. phytochemicals modulate gene expression levels of Nrf2-target genes in the undifferentiated HL-60 cell line. (A) Human acute myeloid leukemia cell line HL-60 gene expression profile in response to SFN, CQA, and C3G exposure at different concentrations by qRT-PCR. Represented as the fold change between condition and the vehicle group. Values outside the range represented in dark blue; (B) Significant changes in oxidative stress genes by RT-qPCR. All values are represented as the fold change of relative RNA expression between the condition and the vehicle group. Statistical analyses were performed using Kruskal–Wallis one-way analysis of variance and Dunn’s post hoc analysis. All values are given as mean ± SD. *p < 0.05, **p < 0.01. SFN, sulforaphane; CQA, Chlorogenic acid; C3G, cyanidin-3-glucoside chloride; I3C, indole-3-carbinol; DIM, 3,3′-Diindolmethane.

3. Discussion

Previous epidemiological studies have shown an inverse association between the consumption of vegetables from the Brassicaceae family and the risk of developing lung [37], breast [38], and prostate cancer [39]. In this context, phytochemicals (GSL and phenolic compounds) from cruciferous foods, have been largely studied for their anticancer potential [40–42]. However, knowledge about the anti-tumoral activity of cruciferous-derived bioactive compounds against AML is still scarce. Thus, in this study, we performed an in vitro study focusing on the potential anti-tumor/cytotoxic activity of a series of Brassica spp. natural compounds in the human AML cell line HL-60. Our results revealed that among 10 different compounds tested, the treatment of HL-60 cells with SFN, CQA, and C3G, displayed remarkable anti-AML activity, as they were able to significantly reduce the viability of undifferentiated leukemia cells with low IC\textsubscript{50} values.

Several in vitro and in vivo studies have allowed for the identification of several mechanisms involved in the anti-carcinogenic effect of SFN including cell cycle arrest, induction of apoptosis, inhibition of angiogenesis, and induction of Phase II and antioxidant en-
zymes [14,43]. In this study, we found that, among the different compounds tested, SFN was the one displaying the most potent cytotoxic effect, which is in line with previous results from other authors [44,45]. Similarly, the anti-tumoral activity of anthocyanins and hydroxycinnamic acids was evaluated against AML exerting a synergic activity with antineoplastic drugs [11]. Our study revealed that the anthocyanin C3G and the hydroxycinnamic acid CQA were able to exert potent cytotoxic effects at relatively low concentrations after 48 h. These results are partially in agreement with those from other authors. For instance, a previous study of the anti-carcinogenic effect of C3G cells showed that this compound inhibited the proliferative capacity of HL-60 cells through p53-independent apoptosis induction together with an increased cytodifferentiation [46]. However, the concentrations needed to reach such capacity were considerably higher (>100 µM) than the ones tested in this work [46]. Likewise, there is certain controversy about the effect of the CQA acid on HL-60 cell viability. Thus, similar to some previous results [47], but in contrast to others [48], our data showed that CQA also has a mild, but significant, cytotoxic effect on human HL-60 leukemia cells. Finally, from the other 7 compounds tested, only the indolic metabolites I3C and 3,3′-Diindolmethane (DIM) showed a mild but significant cytotoxic effect after 24 h.

The anti-carcinogenic activity of ITC has been largely studied over the last 30 years [27]. Importantly, a number of studies have proven that many of these compounds could exert these effects through the activation of the NRF2 pathway [49]. NRF2, which is encoded by the NFE2L2 gene, is a master regulator of the antioxidant response that involves not only antioxidant enzymes but also phase II detoxifying enzymes [50]. Hence, here we evaluated the impact of the selected compounds on genes involved in the NRF2 pathway such as the NFE2L2 modulator KEAP1 and the downstream products HMOX1, NQO1, and GSTA1. Our results showed that the expression of NRF2-regulated genes increased in a dose-dependent manner. However, although a tendency was observed in HMOX1 and GSTA1, this was not significant enough. On the other hand, the expression of the phase I oxidation enzyme gene NQO1 was significantly induced by all three compounds at the highest concentration (Figure 3). Although activation of NQO1 can act as a tumor suppressor, a “Janus” effect of NQO1 in cancer has been suggested [51]. Thus, while some studies have described an anti-tumoral effect through quinone detoxification, superoxide scavenging, and antioxidant maintenance [52], other authors have found that cancer cells such as melanoma, colorectal cancer, or breast cancer overexpress this enzyme, which confers malignant cells protection against oxidative stress [53–55]. Since the anti-leukemic effects occurred in parallel to a significant induction of NQO1 mRNA levels, NQO1 could have anti-cancer activity in this human AML model.

4. Materials and Methods

4.1. Compounds

The GSL glucoraphanin (GRA), glucorucin (GER), and glucobrassicin (GBS) were all obtained of high-purity standards from Phytoplan Diehm and Neuberger GmbH (Heidelberg, Germany). SFN, I3C, and DIM, were all obtained from LKT Laboratories, Inc. (St. Paul, MN, USA). The hydroxycinnamic acids CQA and SIA), as well as the anthocyanin C3G, were obtained from Phytoplan Diehm and Neuberger GmbH (Heidelberg, Germany).

4.2. Preparation of Compounds for In Vitro Assays

The stock solution of each compound was prepared in phosphate-buffered saline (PBS) (Biowest, Bradenton, FL, USA) at a concentration of 1 mg/mL except for SFN. Due to the low solubility of SFN in aqueous solutions, this was first dissolved in dimethyl sulfoxide (DMSO) at 10 mg/mL and then diluted in PBS at a 1:10 ratio. This solution represents 1 mg/mL of SFN with 10% DMSO and was used to prepare successive solutions at the appropriate concentrations in a complete culture medium, prior to being used in the in vitro assays. The media of cells exposed to the highest concentration of SFN
contained 0.09% v/v DMSO. Compound solutions were added to the cells to obtain the final assay concentrations.

4.3. Cell Culture

The human acute myeloid leukemia cell line HL-60 (ATCC® CCL-240™) was used to test the Brassica spp. phytochemicals. Maintenance of the cells was performed as previously described [33]. Briefly, cells were grown in RPMI-1640 medium (Biowest) supplemented with 10% fetal bovine serum (FBS; Gibco, Thermo Fisher Scientific, Madrid, Spain) and 1% penicillin/streptomycin (Gibco, Thermo Fisher Scientific, Madrid, Spain), at 37 °C with 5% CO₂ and 90% humidity. All in vitro assays were performed after passage number 5 and before passage number 20 with cells growing at an exponential ratio.

4.4. In Vitro Cytotoxicity Assays

The anti-tumor activity of the compounds was evaluated by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) viability assays as described previously [32,33]. In brief, HL-60 cells were cultured at a concentration of 10⁵ cells/mL (exponential growth rate) in 96-well plates containing 200 µL of cell culture medium and exposed to different doses of the tested compounds (0.5 µM, 1 µM, 5 µM, 10 µM, 25 µM, and 50 µM) for 24, 48, and 72 h. Then, MTT (Thermo Fisher) was added at a final concentration of 483 µM (0.2 mg/mL) and cells were incubated for 1 h at 37 °C and 5% CO₂. Afterward, cells were lysed using an acidified isopropanol solubilization solution containing 0.04 M hydrochloric acid and 0.1% NP-40 detergent to release the formazan. Finally, the absorbance was measured at 550 nm using a SPECTROstar Nano (BMG Labtech, Germany) plate reader. The compound cytotoxicity was normalized to the control conditions (untreated with an equivalent dose of vehicle (DMSO) when applicable).

In order to test the specificity of the compounds as potential anti-tumor/cytotoxic agents with no collateral negative effects upon non-proliferative cells, the series of compounds were also assayed in an in vitro model of human macrophage-like cells derived from the same HL-60 cell line. To obtain these differentiated macrophage-like cells, HL-60 human leukemia cells growing at an exponential rate in suspension were exposed to a dose of 10 ng/mL of phorbol myristate acetate (PMA) (Sigma-Aldrich, Merck, Alcalá de Vínculos SL, Tomelloso, Spain) for 24 h in 96-well plates at a cell density of 0.2·10⁶ HL-60 cells/well at 37 °C and 5% CO₂. Cells were then incubated in culture media without PMA for another 24 h in the same culture conditions. After differentiation and resting periods, differentiated cells were treated for 48 h with compound solutions at different concentrations. Finally, MTT assays were performed as previously explained to measure cell viability. All experiments were performed in triplicate and in three independent experiments.

4.5. Gene Expression Assays

Total RNA was extracted from HL-60 cells using the GenElute Mammalian Total RNA Miniprep kit (Sigma) following the manufacturer’s instructions. RNA was eluted in RNAse-free water and checked for concentration and purity using the Nanodrop spectrophotometer system (ND-100 3.3. Nanodrop Technologies, Thermo Scientific, Madrid, Spain). Only samples with a ratio of Abs260/Abs280 between 1.8 and 2.1 were used for gene expression assays. cDNA was generated using a high-capacity RNA-to-cDNA kit (Thermo Fisher Scientific, Madrid, Spain) according to the manufacturer’s protocol. PCR amplification was carried out with PowerUp SYBR Green PCR Master Mix (Applied Biosystems, Waltham, MA, USA) using a Fast 7500 Real-Time instrument (Applied Biosystems, Waltham, MA, USA). The sequences of the primers are presented in Table S1. The obtained data were analyzed using the 7500 SDS software (Applied Biosystems, Waltham, MA, USA). Actin beta (ACTB) and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were used as reference genes. Both were considered suitable reference genes for gene expression normalization based on geNorm and/or Bestkeeper stability analysis [34–36]. The gene-stability measures were performed using the ReFinder tool [36]. Relative expression was
calculated using the $2^{-\Delta\Delta Ct}$ method. All experiments were performed in triplicate and in three independent experiments.

4.6. Statistical Analysis

Data were analyzed using the Prism 9.0 program (GraphPad Software Inc., La Jolla, CA, USA) using the Kruskal–Wallis one-way analysis of variance on ranks test followed by Dunn's post hoc analysis. All values are given as mean \( \pm SD \). A level of $p < 0.05$ was considered statistically significant.

5. Conclusions

In this study, the bioactive compounds induced significant cytotoxic effects on the AML human cell line HL-60. These bioactive compounds have been described as anti-inflammatory agents [56], and therefore, they could not only contribute to the stop the progression of carcinogenesis but also reduce systemic inflammation in patients with cancer. Despite these promising results, further research is guaranteed for the evaluation of ingredients and foods rich in bioactive compounds from Brassica spp. (glucosinolates/isothiocyanates and phenolic compounds) to validate these beneficial effects by the bioaccessible and bioavailable metabolites ingested, going from preclinical models to nutritional interventions in cancer and chronic pathologies.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms232113400/s1.

Author Contributions: Conceptualization, B.R.-M., D.A.M. and A.J.R.-A.; methodology, M.Á.N.-S., M.A.M.-S., M.V.-S., P.G.-I., A.O.B. and A.J.R.-A.; validation, D.A.M., B.R.-M. and A.J.R.-A.; formal analysis, M.Á.N.-S., M.A.M.-S., M.V.-S., P.G.-I., A.O.B. and A.J.R.-A.; investigation, all authors; resources, B.R.-M., D.A.M. and A.J.R.-A.; data curation, M.Á.N.-S., B.R.-M., D.A.M. and A.J.R.-A.; writing—original draft preparation, All authors; writing—review and editing, M.Á.N.-S., B.R.-M., D.A.M. and A.J.R.-A.; visualization, B.R.-M., D.A.M. and A.J.R.-A.; supervision, B.R.-M., D.A.M. and A.J.R.-A.; project administration B.R.-M., D.A.M. and A.J.R.-A.; funding acquisition, D.A.M. and B.R.-M. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Fundación Séneca–Murcia Regional Agency for Science and Technology (Comunidad Autónoma de la Región de Murcia, CARM), through the grant number 20855/PI/18); and, by the Institute of Health “Carlos III” (ISCIII), and co-funded by the Fondo Europeo de Desarrollo Regional-FEDER (grant number PI20/00505). M.A.M.-S. was supported by a PFIS contract from the ISCIII (FI21/00003, ISCIII, Spain; co-funded by the Fondo Europeo de Desarrollo Regional-FEDER). B.R.-M. was supported by the “Miguel Servet Type I” program (CP19/00098, ISC III, Spain; co-funded by the Fondo Europeo de Desarrollo Regional-FEDER).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable, data would be available from coauthors upon request.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Kantarjian, H. Acute myeloid leukemia-Major progress over four decades and glimpses into the future. Am. J. Hematol. 2016, 91, 131–145. [CrossRef] [PubMed]
2. Kantarjian, H.; Kadia, T.; DiNardo, C.; Daver, N.; Borthakur, G.; Jabbour, E.; Garcia-Manero, G.; Konopleva, M.; Ravandi, F. Acute myeloid leukemia: Current progress and future directions. Blood Cancer J. 2021, 11, 41. [CrossRef] [PubMed]
3. Mayer, K.; Hahn-Ast, C.; Schwab, K.; Schmidt-Wolf, I.G.H.; Brossart, P.; Glasmancher, A.; Von Lilienfeld-Toal, M. Long-term follow-up of Cladribine, high-dose Cytarabine, and Idarubicin as salvage treatment for relapsed acute myeloid leukemia and literature review. Eur. J. Haematol. 2020, 104, 538–545. [CrossRef]
4. Rawat, P.S.; Jaiswal, A.; Khurana, A.; Bhatti, J.S.; Navik, U. Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed. Pharmacother. 2021, 139, 111708. [CrossRef] [PubMed]
5. Richardson, D.R.; Green, S.D.; Foster, M.C.; Zeidner, J.F. Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options. *Curr. Hematol. Malig. Rep.* 2021, 16, 97–111. [CrossRef]

6. van Gils, N.; Denkers, E.F.; Smits, L. Escape From Treatment: the Different Faces of Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia. *Front. Oncol.* 2021, 11, 659253. [CrossRef]

7. Fajardo-Ordúña, G.; Ledesma-Martínez, E.; Agúltiga-Sánchez, I.; Mora-García, M.; Weiss-Steider, B.; Santiago-Osorio, E. Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review. *Int. J. Mol. Sci.* 2021, 22, 4955. [CrossRef]

8. Liu, H. Emerging agents and regimens for AML. *J. Hematol. Oncol.* 2021, 14, 49. [CrossRef]

9. Thol, F.; Heuser, M. Treatment for Relapsed/Refractory Acute Myeloid Leukemia. *HemaSphere* 2021, 5, e572. [CrossRef]

10. Capuano, E.; Dekker, M.; Verkerk, R.; Oliviero, T. Food as Pharma? The Case of Glucosinolates. *Curr. Pharm. Des.* 2017, 23, 2697–2721. [CrossRef]

11. Cotoraci, C.; Ciceu, A.; Sasu, A.; Miutescu, E.; Hermenean, A. The Anti-Leukemic Activity of Natural Compounds. *Molecules* 2021, 26, 2709. [CrossRef]

12. Lenzi, M.; Cocchi, V.; Malaguti, M.; Barbalace, M.C.; Marchionni, S.; Hrelia, S.; Hrelia, P. 6-(Methylsulfonyl) hexyl isothiocyanate as potential chemopreventive agent: Molecular and cellular profile in leukaemia cell lines. *Oncotarget* 2017, 8, 111697–111714. [CrossRef]

13. Lenzi, M.; Malaguti, M.; Cocchi, V.; Hrelia, S.; Hrelia, P. Castanea sativa Mill. bark extract exhibits chemopreventive properties triggering extrinsic apoptotic pathway in Jurkat cells. *BMC Complement. Altern. Med.* 2017, 17, 251. [CrossRef]

14. Prashar, A.; Siddiqui, F.; Singh, A.K. Synthetic and green vegetable isothiocyanates target red blood leukemia cancers. *Fitoterapia* 2012, 83, 255–260. [CrossRef]

15. Verkerk, R.; Schreiner, M.; Krumbein, A.; Ciska, E.; Holst, B.; Rowland, I.; De Schrijver, R.; Hansen, M.; Gerhauser, C.; Mithen, R.; et al. Glucosinolates in Brassica vegetables: The influence of the food supply chain on intake, bioavailability and human health. *Mol. Nutr. Food Res.* 2009, 53 (Suppl. 2), S219. [CrossRef]

16. Houghton, C.A. Sulforaphane: Its “Coming of Age” as a Clinically Relevant Nutraceutical in the Prevention and Treatment of Chronic Disease. *Oxidative Med. Cell. Longev.* 2019, 2019, 2716870. [CrossRef]

17. Royston, K.J.; Tollefsbol, T.O. The Epigenetic Impact of Cruciferous Vegetables on Cancer Prevention. *Curr. Pharmcol. Rep.* 2015, 1, 46–51. [CrossRef]

18. Sita, G.; Hrelia, P.; Tarozzi, A.; Morroni, F. Isothiocyanates Are Promising Compounds against Oxidative Stress, Neuroinflammation and Cell Death that May Benefit Neurodegeneration in Parkinson’s Disease. *Int. J. Mol. Sci.* 2016, 17, 1454. [CrossRef] [PubMed]

19. Esteve, M. Mechanisms Underlying Biological Effects of Cruciferous Glucosinolate-Derived Isothiocyanates/Indoles: A Focus on Metabolic Syndrome. *Front. Nutr.* 2020, 7, 111. [CrossRef] [PubMed]

20. Kobayashi, M.; Li, L.; Iwamoto, N.; Nakajima-Takagi, Y.; Kaneko, H.; Nakayama, Y.; Eguchi, M.; Wada, Y.; Kumagai, Y.; Yamamoto, M. The Antioxidant Defense System Keap1-Nrf2 Comprises a Multiple Sensing Mechanism for Responding to a Wide Range of Chemical Compounds. *Mol. Cell. Biol.* 2009, 29, 493–502. [CrossRef] [PubMed]

21. Quirante-Moya, S.; García-Ibáñez, P.; Quirante-Moya, F.; Villaño, D.; Moreno, D.A. The Role of Brassica Bioactives on Human Health: Are We Studying It the Right Way? *Molecules* 2020, 25, 1591. [CrossRef] [PubMed]

22. Yeger, H.; Mokhtari, R.B. Perspective on dietary isothiocyanates in the prevention, development and treatment of cancer. *J. Cancer Metastasis Treat.* 2020, 2020, 26. [CrossRef]

23. Abellán, A.; Dominguez-Perles, R.; Moreno, D.A.; García-Viguera, C. Sorting out the Value of Cruciferous Sprouts as Sources of Bioactive Compounds for Nutrition and Health. *Nutrients* 2019, 11, 429. [CrossRef]

24. Baenas, N.; Francisco, M.; Velasco, P.; Cartea, M.E.; García-Villegas, C.; Moreno, D.A. Bioactive Compounds from Brassicaceae as Health Promoters. In *Natural Bioactive Compounds from Fruits and Vegetables as Health Promoters: Part II*; da Silva, L.R., Silva, B.M., Eds.; Bentham Science Publisher: Sharjah, United Arab Emirates, 2016; pp. 27–47. [CrossRef]

25. Moreno, D.A.; Carvajal, M.; López-Berenguer, C.; García-Viguera, C. Chemical and biological characterisation of nutraceutical compounds of broccoli. *J. Pharm. Biomed. Anal.* 2006, 41, 1508–1522. [CrossRef] [PubMed]

26. Baenas, N.; Wagner, A.E. Pharmacopeigenericas of Brassica-Derived Compounds. In *Pharmacopeigenericas*; Academic Press: Cambridge, MA, USA, 2019; pp. 847–857. [CrossRef]

27. Russo, M.; Spagnuolo, C.; Russo, G.L.; Skalicka-Woźniak, K.; Daglia, M.; Sobarzo-Sánchez, E.; Nabavi, S.F. Nrf2 targeting by sulforaphane: A potential therapy for cancer treatment. *Crit. Rev. Food Sci. Nutr.* 2017, 58, 1391–1405. [CrossRef]

28. Houghton, C.A.; Fassett, R.G.; Coombes, J.S. Sulforaphane and Other Nutrigenomic Nrf2 Activators: Can the Clinician’s Expectation Be Matched by the Reality? *Oxid. Med. Cell. Longev.* 2016, 2016, 7857186. [CrossRef] [PubMed]

29. Yu, C.; Xiao, J.-H. The Keap1-Nrf2 System: A Mediator between Oxidative Stress and Aging. *Oxidative Med. Cell. Longev.* 2021, 2021, 6635460. [CrossRef]

30. Meechcate, H.; de Oliveira, R.C.; Es-Safi, I.; Mourão, E.V.; Bouhrim, M.; Kyrychuk, A.; Pontes, G.S.; Bousta, D.; Grafov, A. Antileukemic Activity and Molecular Docking Study of a Polyphenolic Extract from Coriander Seeds. *Pharmaceuticals* 2021, 14, 770. [CrossRef]

31. Zhu, W.J.; Lin, L.P.; Liu, D.; Qian, J.C.; Zhou, B.B.; Yuan, D.D.; Tan, R.X. Pharmacophore-inspired discovery of FLT3 inhibitor from kimchi. *Food Chem.* 2021, 361, 130139. [CrossRef]
32. Guirado, A.; Sánchez, J.L.L.; Ruiz-Alcaraz, A.J.; Bautista, D.; Gálvez, J. Synthesis and biological activity of 4-alkoxy-6,9-dichloro[1,2,4]triazolo[4,3-a]quinoxalines as inhibitors of TNF-α and IL-6. *Eur. J. Med. Chem.* 2012, 54, 87–94. [CrossRef]

33. Ruiz-Alcaraz, A.J.; Martínez-Sánchez, M.A.; García-Peñarrubia, P.; Martínez-Esparriza, M.; Ramos-Molina, B.; Moreno, D.A. Analysis of the anti-inflammatory potential of Brassica bioactive compounds in a human macrophage-like cell model derived from HL-60 cells. *Biomed. Pharmacother.* 2022, 149, 112804. [CrossRef] [PubMed]

34. Pfaffl, M.W.; Tichopad, A.; Prgomet, C.; Neuvians, T.P. Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper—Excel-based tool using pair-wise correlations. *Biotechnol. Lett.* 2004, 26, 509–515. [CrossRef] [PubMed]

35. Vandesompele, J.; De Preter, K.; Pattyn, F.; Poppe, B.; Van Roy, N.; De Paepe, A.; Speleman, F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. * Genome Biol.* 2002, 3, RESEARCH0034. [CrossRef] [PubMed]

36. Xie, F.; Xiao, P.; Chen, D.; Xu, L.; Zhang, B. miRDeepFinder: A miRNA analysis tool for deep sequencing of plant small RNAs. *Plant Mol. Biol.* 2012, 80, 75–84. [CrossRef] [PubMed]

37. Egner, P.A.; Chen, J.-G.; Zarth, A.T.; Ng, D.K.; Wang, J.-B.; Kessler, K.H.; Jacobson, L.P.; Muñoz, A.; Johnson, J.L.; Groopman, J.D.; et al. Rapid and Sustainable Detoxification of Airborne Pollutants by Broccoli Sprout Beverage: Results of a Randomized Clinical Trial in China. *Cancer Prev. Res.* 2014, 7, 813–823. [CrossRef]

38. Zhang, Z.; Atwell, L.L.; E Farris, P.; Ho, E.; Shannon, J. Associations between cruciferous vegetable intake and selected biomarkers among women scheduled for breast cancer screening. *Public Health Nutr.* 2015, 19, 1288–1295. [CrossRef]

39. Traka, M.H.; Melchini, A.; Coode-Bate, J.; Al Kadhi, O.; Saha, S.; Defe.renz, M.; Troncoso-Rey, P.; Kibblewhite, H.; O'Neill, C.M.; Bernuzzi, F.; et al. Transcriptional changes in prostate of men on active surveillance after a 12-mo glucoraphanin-rich broccoli intervention-results from the Effect of Sulforaphane on prostate Cancer PrEvention (ESCAPE) randomized controlled trial. *Am. J. Clin. Nutr.* 2019, 109, 1133–1144. [CrossRef]

40. Crowley, E.; Rowan, N.J.; Friel, A.M. Natural and Synthetic Isothiocyanates Possess Anticancer Potential Against Liver and Prostate Cancer In Vitro. *Anticancer Res.* 2019, 39, 3469–3485. [CrossRef]

41. Ding, Y.; Paonessa, J.D.; Randall, K.L.; Argoti, D.; Chen, L.; Vouros, P.; Zhang, Y. Sulforaphane inhibits 4-aminobiphenyl-induced DNA damage in bladder cells and tissues. *Carcinogenesis* 2010, 31, 1999–2003. [CrossRef]

42. Yamaguchi, M.; Murata, T.; Ramos, J.W. The phytochemical p-hydroxycinnamic acid suppresses the growth and stimulates the DNA damage in bladder cells and tissues. *Carcinogenesis* 2010, 31, 1999–2003. [CrossRef]

43. Wang, F.P.; Qiao, C.J.; Sun, Y.W.; Li, X.Y.; Huang, X.Y.; Zhang, W.R.; Wang, X.; Wang, M.Y. Effect and Mechanism of Sulforaphane on G2/M Phase Arrest of Acute Myeloid Leukemia KG1a and KG1 Cells. *Zhongguo Shi Yan Xue Ye Xue Za Zhi* 2021, 29, 1050–1055. [CrossRef] [PubMed]

44. Shang, H.-S.; Shih, Y.-L.; Lee, C.-H.; Tsai, C.-H.; Liu, J.-Y.; Liao, N.-C.; Chen, Y.-L.; Huang, Y.-P.; Lu, H.-F.; Chung, J.-G. Sulforaphane-induced apoptosis in human leukemia HL-60 cells through extrinsic and intrinsic signal pathways and altering associated genes expression assayed by cDNA microarray. *Environ. Toxicol.* 2016, 32, 311–328. [CrossRef] [PubMed]

45. Steverding, D.; Michaels, S.; Read, K.D. In Vitro and In Vivo Studies of Trypanocidal Activity of Dietary Isothiocyanates. *Planta Medica* 2014, 80, 183–186. [CrossRef]

46. Fimognari, C.; Berti, F.; Nässe, M.; Cantelli-Forti, G.; Hrelia, P. Induction of apoptosis in two human leukemia cell lines as well as differentiation in human promyelocytic cells by cyanidin-3-O-β-glucopyranoside. *Biochem. Pharmacol.* 2004, 67, 2047–2056. [CrossRef]

47. Liu, Y.-J.; Zhou, C.-Y.; Qiu, C.-H.; Lu, X.-M.; Wang, Y.-T. Chlorogenic acid induced apoptosis and proliferation in human acute promyelocytic leukemia HL-60 cells. *Mol. Med. Rep.* 2013, 8, 1106–1110. [CrossRef] [PubMed]

48. Hernandez, L.C.; Machado, A.R.T.; Tuttis, K.; Ribeiro, D.L.; Aissa, A.F.; Devoz, P.P.; Antunes, L.M.G. Caffeic acid and chlorogenic acid cytotoxicity, genotoxicity and impact on global DNA methylation in human leukemic cell lines. *Genet. Mol. Biol.* 2020, 43, e20190347. [CrossRef] [PubMed]

49. Soundararajan, P.; Kim, J.S. Anti-Carcinogenic Glucosinolates in Cruciferous Vegetables and Their Antagonistic Effects on Prevention of Cancers. *Molecules* 2018, 23, 2983. [CrossRef]

50. Hybertson, B.M.; Gao, B.; Bose, S.K.; McCord, J.M. Oxidative stress in health and disease: The therapeutic potential of Nrf2 activation. * Mol. Asp. Med.* 2011, 32, 234–246. [CrossRef]

51. Zhang, K.; Cheng, D.; Ma, K.; Wu, X.; Hao, H.; Jiang, S. NAD(P)H:Quinone Oxidoreductase 1 (NQO1) as a Therapeutic and Diagnostic Target in Cancer. *J. Med. Chem.* 2018, 61, 6983–7003. [CrossRef]

52. Ross, D.; Siegel, D. The diverse functionality of NQO1 and its roles in redox control. *Redox Biol.* 2021, 41, 101950. [CrossRef] [PubMed]

53. Garate, M.; Wani, A.A.; Li, G. The NAD(P)H:Quinone Oxidoreductase 1 induces cell cycle progression and proliferation of melanoma cells. *Free Radic. Biol. Med.* 2010, 48, 1601–1609. [CrossRef]

54. Oh, E.-T.; Kim, J.-W.; Kim, J.M.; Kim, S.J.; Lee, J.-S.; Hong, S.-S.; Goodwin, J.I.; Ruthenborg, R.J.; Jung, M.G.; Lee, H.-J.; et al. NQO1 inhibits proteasome-mediated degradation of HIF-1α. *Nat. Commun.* 2016, 7, 13939. [CrossRef]

55. Zhu, K.; Li, Y.; Deng, C.; Wang, Y.; Piao, J.; Lin, Z.; Chen, L. Significant association of PKM2 and NQO1 proteins with poor prognosis in breast cancer. *Pathol. Res. Pract.* 2020, 216, 153173. [CrossRef]
56. Connolly, E.L.; Sim, M.; Travica, N.; Marx, W.; Beasy, G.; Lynch, G.S.; Bondonno, C.P.; Lewis, J.R.; Hodgson, J.M.; Blekkenhorst, L.C. Glucosinolates From Cruciferous Vegetables and Their Potential Role in Chronic Disease: Investigating the Preclinical and Clinical Evidence. *Front. Pharmacol.*, **2021**, *12*, 767975. [CrossRef]